Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers.
Incyclix Bio has raised $5.0M in total funding. The most recent round was Series B. The last funding was announced in April 2026.
Incyclix Bio's investors include RA Capital Management, Hatteras Venture Partners, Eli Lilly & Company Foundation, Cape Fear BioCapital, Boxer Capital.
Incyclix Bio is headquartered in Durham, United States.
Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers.
Incyclix Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Incyclix Bio — Funding & Investors." VCBacked, April 8, 2026, https://www.vcbacked.co/company/incyclix-bio. Accessed July 19, 2026.
VCBacked. (2026). Incyclix Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/incyclix-bio
{{cite web |title=Incyclix Bio — Funding & Investors |url=https://www.vcbacked.co/company/incyclix-bio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated